Without reducing death or major bleeding, Toby Rogers says the results can be interpreted based on one’s ‘starting ...

While no comparable guidelines exist in the US, Richard Kovacs of the ACC said he considers it to be “eye-opening.” ...

This month, readers gravitated most toward the memory of David Taggart. Stories interpreting data from ESC 2026 also drew ...

As the first trial of these valve interventions to impact HF hospitalization and mortality, it “feels like a COAPT-like ...

The lack of impact on outcomes was surprising, says the investigator, though the FAST-CTCA trial may still come through.

While there was no change in disability-free survival, the results should impact guidelines, says François Mach.

September 2, 2026 | Saibal Kar and C. Michael Gibson look at the 2-year outcomes of transcatheter edge-to-edge repair for tricuspid regurgitation. Receive the the latest news, research, and ...

Among patients with nonobstructive hypertrophic cardiomyopathy (HCM), the selective cardiac myosin inhibitor aficamten ...

SWITCH-SWEDEHEART’s unique design randomized healthcare regions but wasn’t a head-to-head comparison with ticagrelor.

An intervention in rural China continued to impact hypertension, CV events, and dementia risk 4 years after it ended.

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...

Two different direct oral anticoagulant (DOAC) strategies following successful TAVI in patients without another indication for oral anticoagulation provided conflicting results in the ACASA-TAVI and ...